Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04205604 · ClinicalTrials.gov registry record · Phase 2
18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism
A Phase 2 study of Congenital Hyperinsulinism, sponsored by Miguel Pampaloni.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 50
- Enrollment target
- 1
- Study location
NCT04205604 is a Phase 2 study of Congenital Hyperinsulinism that is actively recruiting participants, run by Miguel Pampaloni. The registered enrollment target is 50 participants, below the 71-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (30% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04205604, a Phase 2 study of Congenital Hyperinsulinism, is actively recruiting participants, sponsored by Miguel Pampaloni.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 50 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.
Conditions Studied
Interventions
- DRUG 18F-Fluoro Dopa Imaging
Study Locations (1)
California
- University of California, San Francisco - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2016-11-03 |
| Est. Completion | 2025-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04205604
The ClinicalTrials.gov registry entry for NCT04205604 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 71-participant average among 7 other Congenital Hyperinsulinism trials with a reported enrollment target (30% lower). The listed sponsor is Miguel Pampaloni, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Congenital Hyperinsulinism appearing as the primary indexed condition, and to 1 intervention - of which 18F-Fluoro Dopa Imaging is the first listed.
NCT04205604 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04205604 about?
NCT04205604 is a clinical study titled "18FluoroLDOPA PET Imaging for the Detection and Localization of Focal Congenital Hyperinsulinism". The goal of this project is to determine the role of FDOPA/PET as a pre-operative diagnostic imaging procedure for differentiating focal and diffuse forms of congenital hyperinsulinism and locating focal lesions in the pancreas to guide surgical resection.
What is the current status of trial NCT04205604?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 50 participants. The study started on 2016-11-03. Estimated completion is 2025-12-31.
What conditions does trial NCT04205604 study?
This clinical trial studies the following conditions: Congenital Hyperinsulinism.
What interventions are being tested in trial NCT04205604?
The interventions under investigation include: 18F-Fluoro Dopa Imaging (DRUG).
Who is sponsoring clinical trial NCT04205604?
This trial is sponsored by Miguel Pampaloni, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04205604 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Congenital Hyperinsulinism
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
RECRUITING · Phase 2
-
Trial Evaluating Efficacy and Safety of Dasiglucagon in Children With Congenital Hyperinsulinism
COMPLETED · Phase 2
-
Utility of [F-18] fluoroDOPA for Neonatal Hyperinsulinism
COMPLETED · Phase 2
-
Fluorodopa F 18 in Congenital Hyperinsulinism and Insulinoma
RECRUITING · Phase 1
-
RZ358 Treatment for Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
-
Extension Trial Evaluating the Long-term Safety and Efficacy of Dasiglucagon in Children With Congenital Hyperinsulinism
ACTIVE NOT RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.